Abstract Background: Type 2 diabetes mellitus (T2DM) is an independent risk factor for osteoporosis, increasing the risk of fractures and poor prognosis
The oral tablet form of Rybelsus represents a breakthrough in convenience and patient preference, addressing one of the major barriers to adherence with injectable diabetes medications
Continuing from what was previously discussed, the transcription factors and essential pathways involved in the initiation and promotion of apoptosis and necrosis are the p53 factor, the mitogen-activated protein kinase pathways, NF-B, and caspases
These side effects are real and deserve clinical attention, and they should be managed by a physician experienced in obesity medicine
These medications are long-acting versions of other GLP-1 medications that have been on the market for over a decade such as liraglutide (Victoza, Saxenda), dulaglutide (Trulicity) or exenatide (Byetta, Bydureon)